Beacon Equity Issues Trading Overview for Keryx Biopharmaceuticals

• Press Release
• Source: Beacon Equity
• On 6:50 am EDT, Thursday October 15, 2009

DALLAS, Oct. 15, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals (Nasdaq:KERX - News). The report includes financial and comparative analyses, and pertinent industry information you need to know for an educated investment decision.

Related Quotes

Symbol	Price	Change
KERX	2.38	0.00

{"s" : "kerx,kg,pfe,wpi","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The investment report on Keryx Biopharmaceuticals (Nasdaq:KERX - News) should be of particular interest to comparable companies: Watson Pharmaceuticals Inc (NYSE:WPI - News), King Pharmaceuticals Inc. (NYSE:KG - News) and Pfizer Inc. (NYSE:PFE - News).

It is available at: http://www.beaconequity.com/i/KERX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Keryx Biopharmaceuticals Inc. (KERX) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases including renal disease and cancer.

In the report, the analyst notes:

"KERX last month announced that its drug candidate, Zerenex, was well tolerated and safe in a mid-stage study that was testing it specifically for long-term use in patients with end-stage renal disease; this news sending its shares to a new 52-week high. Zerenex is an oral, iron-based compound that attaches itself to phosphates when food is broken down in the stomach to form non-absorbable complexes. The late-stage study for the kidney drug is expected to begin at the end of the year.

"The net income for the second quarter ended June 30, 2009, was $14.1 million, or $0.29 per diluted share, compared to a net loss of $7.7 million, or $0.17 per share, for the second quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $18.0 million in license revenue relating to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii), which eliminated the Company's significant ongoing obligations included in the original agreement, a $1.8 million decrease in research and development expenses related to KRX-0401."

To read the entire report visit: http://www.beaconequity.com/i/KERX

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in the report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com